Buprenorphine and Metabolites, Serum or Plasma, Quantitative
Also known as: BUPRSP
Use
The test is used to monitor patient adherence to buprenorphine therapy. This includes the detection and quantitation of buprenorphine and its metabolite norbuprenorphine in serum or plasma. The presence of metabolites without the parent drug may indicate use of the parent drug over the prior week.
Special Instructions
For medical purposes only; not valid for forensic use. The cut-off concentration for positive results is 1 ng/mL. Potential interpretive questions should be directed to the laboratory.
Limitations
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, or limitations of testing. This test has not been cleared or approved by the FDA and is intended for clinical purposes.
New York Approved
Methodology
Mass Spectrometry
Biomarkers
LOINC Codes
- 53881-9
- 3413-2
Result Turnaround Time
1-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
1 mL
Container
ARUP standard transport tube
Collection Instructions
Separate serum or plasma from cells ASAP or within 2 hours of collection.
Storage Instructions
Refrigerated
Causes for Rejection
Separator tubes, specimens collected in light blue (sodium citrate), specimens exposed to repeated freeze/thaw cycles, hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 2 weeks |
| Frozen | 3 years |